ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
Dow Jones
43,408.47
0.32%
US Dollar vs MXN
20.32776
0.23%
Brent Oil
73.905
1.46%
Bitcoin
98,019.87
3.87%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Adaptive Biotechnologies Corporation (ADPT) Cotización

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation (ADPT)

Adaptogenics Health Corp
4.42
-0.06
(-1.34%)
Cerrado 20 Noviembre 3:00PM
Delayed by 15 minutes
4.42
0.00
( 0.00% )
Pre Mercado: 3:19AM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
4.42
Postura de Compra
4.42
Postura de Venta
5.36
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
2.28 Rango de 52 semanas 6.70
Capitalización de Mercado [m]
652.301M
Precio Anterior
4.42
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
1,054,815
Acciones en circulación
147,579,486
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.90
Beneficio por acción (BPA)
-1.53
turnover
170.28M
Beneficio neto
-225.25M

Acerca de Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for... Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.adaptivebiotech.com
Sede
Olympia, Washington, USA
Fundado
-
Adaptive Biotechnologies Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ADPT. The last closing price for Adaptive Biotechnologies was US$4.42. Over the last year, Adaptive Biotechnologies shares have traded in a share price range of US$ 2.28 to US$ 6.70.

Adaptive Biotechnologies currently has 147,579,486 shares in issue. The market capitalisation of Adaptive Biotechnologies is US$652.30 million. Adaptive Biotechnologies has a price to earnings ratio (PE ratio) of -2.90.

ADPT Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities

19 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

13 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

08 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Noviembre 2024
Edgar (US Regulatory)

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...

07 Noviembre 2024
GlobeNewswire Inc.

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate...

07 Noviembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

10 Octubre 2024
Edgar (US Regulatory)

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...

09 Octubre 2024
GlobeNewswire Inc.

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...

29 Agosto 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-1.41-24.18524871365.835.834.3314179294.75816664CS
4-0.36-7.531380753144.786.74.3311730785.2453349CS
12-0.13-2.857142857144.556.73.98110548154.94756581CS
260.8824.85875706213.546.72.9912448754.33485748CS
520.020.4545454545454.46.72.2813978783.99212558CS
156-22.96-83.856829802827.3830.512.2812829737.47089103CS
260-24.06-84.480337078728.4871.252.28113111617.84640225CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
ESGROEnstar Group Ltd
US$ 28.00
(40.92%)
28
CCECCapital Clean Energy Carriers Corporation
US$ 24.99
(34.72%)
11
WSBFWaterstone Financial Inc
US$ 9.00
(-40.98%)
4
TRSTriMas Corporation
US$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
US$ 11.00
(-40.15%)
212
PYXSPyxis Oncology Inc
US$ 2.43
(-36.39%)
209.56k
XNCRXencor Inc
US$ 15.11
(-36.30%)
2
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
XTKGX3 Holdings Company Ltd
US$ 0.0775
(-13.89%)
10.83M
CRKNCrown Electrokinetics Corporation
US$ 0.9853
(25.41%)
5.59M

Discusión

Ver feed completo
PonkenPlonken PonkenPlonken 2 minutos hace
Does anyone in here believe SAVA is a scam? Ph3 results coming soon and they already went above and beyond to cheat on the ph1 and ph2 data set. The ph3 data set will be impossible to skew I believe.
GBR GBR 2 minutos hace
In yesterdays Needham conference,

RS said they had 485 employees
VERI
misterfishman misterfishman 2 minutos hace
Of course. Rome conquered and robbed everybody at the time.
IGPK
Truth_is_a_tool Truth_is_a_tool 3 minutos hace
Or not lol . Oh well. Maybe next week 🤷‍♂️
KBLB
Thomas@yahoo Thomas@yahoo 4 minutos hace
Welcome Back and Now Our 47th PRESIDENT OF THE UNITED STATES DONALD J. TRUMP
https://www.marijuanamoment.net/dr-oz-could-elevate-medical-marijuana-support-as-trumps-medicare-and-medicaid-director/

https://www.marijuanamoment.net/fda-approves-long-awaited-clinical-trial-of-smoke
CVSI
IB_ IB_ 4 minutos hace
As we both know "nasrat said" is not even close to a guarantee !!!!!!!!!!!

I only go by what "nasrat did" .....

How many ANDA's has "nasrat said" would be filed in 2024 ???????????

How many were actually filed ???????????

Hey Thanks A Lot
ELTP
GBR GBR 4 minutos hace
Well my take on that is much of the underlying tech with aiWARE is from AWS.

I think aiWARE is basically a patented framework. Using open source tech and AWS tech, but applying it to their own proprietary patented framework or AI operating system as they call it.

Eve
VERI
Konaploinks Konaploinks 4 minutos hace
Up early. Fell asleep early. Watching Fox News. Charles Payne just mentioned he is watching quantum computing to what’s his name? Anyway what his name says oh. Quantum computing? Then it switches to end of segment on to Carly shimkus ? And she says. Quantum computing? I’m going to have to google tha
IONQ
mrMadMax mrMadMax 4 minutos hace
🤡We will give a free tricycle to these two clowns🤡, Jimr1717 and Pickme2, so you can go around and scare "people" with your nonsense. However, nobody will believe this absurdity BS —no one at all. Poor fools; your insinuations are just as ridiculous as you are.🤡 Instead of bo
ATMH
KVM KVM 4 minutos hace
Somebody should just scoop them up for $5 per share and end everyone's misery.
VERI
cashclan cashclan 4 minutos hace
Same reason



You cut and past nothing but left wing opinion articles ...I am just trying to keep up with the Jones.

There is absolutely zero difference other than my posting shed a little more truth.
SHEEPWOLF SHEEPWOLF 5 minutos hace
$ILLR GREEN 12 OF LAST 18 SESSIONS
•STRONG UPTREND INTACT
•ALL DIPS GET EATEN
https://investorshub.advfn.com/uimage/uploads/2024/11/21/buiqeimageedit_36_6627094413.jpg
ILLR
SHEEPWOLF SHEEPWOLF 5 minutos hace
$ILLR GREEN 12 OF LAST 18 SESSIONS
•STRONG UPTREND INTACT
•ALL DIPS GET EATEN
https://investorshub.advfn.com/uimage/uploads/2024/11/21/buiqeimageedit_36_6627094413.jpg
ILLR
quickensupportnumber12 quickensupportnumber12 6 minutos hace
Quicken users, are you stuck with software or account issues? Don’t worry—call +1-888-848-2409 for immediate support. Whether you’re dealing with login troubles, password recovery, or troubleshooting errors, their expert team is available to assist you. Support hours are 5 am to 5 pm PST, seven days
toohot toohot 6 minutos hace
Outstanding post, edbi46! Very well stated for our beloved BIEL. I’ve always preached that patience is the key. And I truly believe that patience is still needed for our beloved BIEL. Just a little longer.




BUY $BIEL$
BIEL
KVM KVM 7 minutos hace
Exactly how do they have the manpower yet they have over 500 employees with a revenue per employee of over 200k. They need at least 225 mil of revs to break even. Their push backed 2026 breakeven projection isn't correct even based on their 30% growth. But again they have never got any #s right.
VERI
Polymer Paul Polymer Paul 8 minutos hace
I think it's pretty obvious... Timelines should have been met... But lebby botched the negotiations being too demanding. And in the end other companies opted for other solutions which probably workout cheaper when you take lebby and marcelli out of the pay packet. This scenario is very very believab
LWLG
na na na na 9 minutos hace
https://www.youtube.com/watch?v=j_QLzthSkfM
THBD
STILL TOWING STILL TOWING 11 minutos hace
You are communicating with a clown I posted the other day financials are necessary to move forward.. The simplest of concepts surprises MRGEs biggest cheerleader..Think about it..The day before delisting the clown posts a buy recommendation..So full of his own bravado..On the fish pipeline,we call
MRGE
JACKPOT JACKPOT 11 minutos hace
The new OTC 😂
BTCUSD
GBR GBR 11 minutos hace
Remember as far back as 2021 when Zemetra
said they needed a services arm, because they couldn't get partners motivated to build on aiWARE. So he said they either had to build it or acquire it.

So they spent 52M on Broadbean in 2023, and now they are launching a consulting bus
VERI
KVM KVM 12 minutos hace
If Veri had any decent Ai tech would have been scooped up a long time ago.
VERI
runncoach runncoach 12 minutos hace
Nope. Never drank it. Made many bags though. Odds are the trial is unsuccessful like all the rest which is why I wouldn't buy in unless price was much, much lower. That said I'm excited to see the results in the next month or so and hope for the best. Shorts could be in for some real trouble in the
SAVA
Implanting Implanting 12 minutos hace
Having talked to Paul as many times as I have, I'm pretty confident that even if he knows the timeline on a deal getting done or when the next dilution may have to take place, he couldn't tell me. That doesn't mean I won't go through the motion of asking the questions.

That $18M in t
FFMGF

Su Consulta Reciente

NASDAQ
ADPT
Adaptive Biotechnologies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados